Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
Zamtocabtagene autoleucel reduced the risk of an event against R-GemOx in transplant-ineligible second-line large B-cell lymphoma, with serious …
A pivotal efficacy study and a separate G-CSF reduction trial could answer different questions, but market projections remain …
Pozdeutinurad produced significant and durable urate lowering in uncontrolled gout, with treatment-emergent adverse-event rates close to placebo
The investigational triple agonist matched semaglutide on average glucose reduction and delivered roughly twice the percentage weight loss …
Interim Phase 1b/2a results showed durable swallowing improvements at the low dose and larger three-month gains at the …
The interim Phase 1b dataset included eight efficacy-evaluable patients at cutoff, with post-cutoff confirmation lifting the reported rate …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Already a subscriber? Log in